Literature DB >> 21446977

Improved survival with recent Post-Transplant Lymphoproliferative Disorder (PTLD) in children with kidney transplants.

V R Dharnidharka1, K L Martz, D M Stablein, M R Benfield.   

Abstract

Post-transplant lymphoproliferative disorder (PTLD) has been associated with high mortality, but recent anecdotal survival appeared better. From 1988 to 2010, the NAPRTCS registry had 235 registered PTLD cases. We sent a special 25-point questionnaire study to the NAPRTCS centers with the most recent 150 cases to obtain additional follow-up data not collected in the master registry, our objective being to determine the recent outcomes after PTLD and determine prognostic factors. We received 92 completed responses, in which only 12 (13%) deaths were reported, 2 from nonmedical causes, 10 with a functioning graft. Kaplan-Meier-calculated patient survival was 90.6% at 1 year and 87.4% at 3, 4 and 5 years post-PTLD. Graft survival post-PTLD was 81.8% at 1 year, 68.0% at 3 years and 65.0% at 5 years. Seven patients received a retransplant after PTLD, with no PTLD recurrence reported. Using all 235 PTLD cases, the covariates associated with better patient survival were more recent year of PTLD diagnosis (adjusted hazard ratio AHR 0.86, p < 0.001), and with worse survival were late PTLD (AHR 1.98, p = 0.0176) and patient age above 13 at PTLD (AHR 3.43, p value 0.022). In children with kidney transplants, patient survival has improved with more recent PTLDs. ©2011 The Authors Journal compilation©2011 The American Society of Transplantation and the American Society of Transplant Surgeons.

Entities:  

Mesh:

Year:  2011        PMID: 21446977     DOI: 10.1111/j.1600-6143.2011.03470.x

Source DB:  PubMed          Journal:  Am J Transplant        ISSN: 1600-6135            Impact factor:   8.086


  15 in total

Review 1.  Primer on renal transplantation.

Authors:  Asha Moudgil
Journal:  Indian J Pediatr       Date:  2012-06-05       Impact factor: 1.967

2.  Non-immunologic allograft loss in pediatric kidney transplant recipients.

Authors:  Isa F Ashoor; Vikas R Dharnidharka
Journal:  Pediatr Nephrol       Date:  2018-02-26       Impact factor: 3.714

Review 3.  Emerging therapeutic strategies for Epstein-Barr virus+ post-transplant lymphoproliferative disorder.

Authors:  Olivia Hatton; Olivia M Martinez; Carlos O Esquivel
Journal:  Pediatr Transplant       Date:  2012-02-21

4.  Pediatric Onco-Nephrology: Time to Spread the Word-Part II: Long-Term Kidney Outcomes in Survivors of Childhood Malignancy and Malignancy after Kidney Transplant.

Authors:  Arwa Nada; Jennifer G Jetton
Journal:  Pediatr Nephrol       Date:  2021-09-06       Impact factor: 3.651

Review 5.  Long-term effects of paediatric kidney transplantation.

Authors:  Christer Holmberg; Hannu Jalanko
Journal:  Nat Rev Nephrol       Date:  2015-12-14       Impact factor: 28.314

6.  Low-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a Children's Oncology Group Report.

Authors:  T G Gross; M A Orjuela; S L Perkins; J R Park; J C Lynch; M S Cairo; L M Smith; R J Hayashi
Journal:  Am J Transplant       Date:  2012-08-06       Impact factor: 8.086

Review 7.  Malignancies after pediatric kidney transplantation: more than PTLD?

Authors:  Martin Mynarek; Kais Hussein; Hans H Kreipe; Britta Maecker-Kolhoff
Journal:  Pediatr Nephrol       Date:  2013-09-24       Impact factor: 3.714

8.  Dual blockade of the PI3K/Akt/mTOR pathway inhibits posttransplant Epstein-Barr virus B cell lymphomas and promotes allograft survival.

Authors:  Adam X Sang; Marla C McPherson; Geoffrey T Ivison; Xiumei Qu; Joseph Rigdon; Carlos O Esquivel; Sheri M Krams; Olivia M Martinez
Journal:  Am J Transplant       Date:  2019-01-09       Impact factor: 8.086

Review 9.  Infectious disease risks in pediatric renal transplantation.

Authors:  Felicia A Scaggs Huang; Lara Danziger-Isakov
Journal:  Pediatr Nephrol       Date:  2018-04-06       Impact factor: 3.651

10.  Malignancies after pediatric solid organ transplantation.

Authors:  Cal Robinson; Rahul Chanchlani; Abhijat Kitchlu
Journal:  Pediatr Nephrol       Date:  2020-10-15       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.